Radiologic Clinics Of North America PET Imaging II, An Issue of Radiologic Clinics Vol 42 Issues 6

Cover ......Page 1 Preface......Page 2 Radiation necrosis......Page 5 Diagnosis of radiation necrosis/tumor recurrence......Page 6 Prognosis......Page 10 PET imaging with alternative tracers......Page 13 Other tracers......Page 14 References......Page 15 General characteristics of l-[18F] 6-fluorodopa......Page 18 Diagnosis of Parkinson's disease......Page 21 Preclinical Parkinson's disease......Page 22 Other PET tracers for studying Parkinson's disease......Page 23 Multiple system atrophy......Page 25 Dopa-responsive dystonia......Page 26 References......Page 27 Solitary pulmonary nodules......Page 32 Conventional diagnostic approach in lung nodules......Page 33 Benign causes of fluorodeoxyglucose uptake......Page 34 Dual time point or delayed imaging for differentiating benign and malignant nodules......Page 35 Partial volume correction for accurate measurement of standardized uptake value......Page 36 Role of somatostatin scintigraphy in lung nodules......Page 37 Hilar and mediastinal lymph node staging......Page 38 Distant metastases......Page 39 Applications in radiation oncology......Page 41 New radiotracers and implications for the future......Page 42 Noninvasive imaging modalities......Page 43 Mesothelioma......Page 44 Distinguishing metabolic patterns for benign and malignant disorders......Page 46 References......Page 47 Applications of fluorodeoxyglucose-PET imaging in the detection of infection and inflammation and other benign disorders......Page 53 HIV and AIDS......Page 54 Orthopedic infections......Page 55 Fever of unknown origin......Page 58 Soft tissue infection and inflammations......Page 59 References......Page 60 Initial staging of melanoma......Page 67 Regional lymph node metastasis......Page 68 Distant metastasis......Page 69 Impact on patient management......Page 73 References......Page 76 Anatomy......Page 78 Oxygen, perfusion, and ventilation perfusion ratios......Page 79 Oxygen measurements......Page 81 Perfusion......Page 82 Ventilation-perfusion ratios......Page 84 Ventilation......Page 85 Diffusion......Page 87 References......Page 88 Hypoxia-induced changes in tumor biology......Page 90 Tumor hypoxia and clinical outcome: what is new?......Page 93 Methods to evaluate tumor hypoxia......Page 95 Polarographic electrode measurements......Page 96 Evaluating angiogenesis......Page 97 PET and hypoxia imaging......Page 98 Nitroimidazole compounds......Page 99 Alternative azomycin imaging agents......Page 101 Summary......Page 103 References......Page 104 Monitoring response to treatment in patients utilizing PET......Page 109 PET imaging and image analysis......Page 110 Lymphoma......Page 112 Gastric and esophageal carcinoma......Page 113 Breast cancer......Page 114 Lymphoma......Page 115 Other tumors......Page 117 Timing of serial PET imaging......Page 118 Imaging cell proliferation......Page 119 Radiolabeled amino acids......Page 120 Summary......Page 121 References......Page 122 Tissue optics......Page 125 Instrumentation......Page 126 Theory......Page 127 Brain imaging......Page 128 Breast imaging......Page 131 Muscle imaging......Page 132 References......Page 134 PET imaging of cellular proliferation......Page 139 Thymidine metabolism and consequences for imaging......Page 140 Thymidine analogues: preclinical studies and quantitative considerations......Page 142 Carbon-11-thymidine (TdR) imaging in patients......Page 144 Patient imaging with fluorothymidine......Page 148 Patient imaging with other thymidine analogues......Page 149 References......Page 150 Rubidium-82-labeled chloride......Page 154 Copper-62-labeled pyruvaldehyde bis (N4-methylthio-semicarbazone)......Page 155 Carbon-11-labeled palmitate and acetate......Page 156 Management of patients with left ventricular dysfunction and coronary artery disease......Page 157 Identification of myocardial viability by PET......Page 158 Predicting cardiac events, remodeling, and long-term survival......Page 159 Diagnosis of coronary artery disease......Page 160 Cardiac neuronal imaging......Page 161 References......Page 162 Patient preparation......Page 167 Epilepsy......Page 168 Cardiac applications......Page 169 Applications in oncology......Page 170 Central nervous system tumors......Page 171 Lymphoma......Page 173 Neuroblastoma......Page 175 Wilms' tumor......Page 176 Soft tissue tumors......Page 177 Summary......Page 178 References......Page 179 Interictal PET imaging......Page 185 Ictal PET imaging......Page 191 Receptor PET imaging......Page 192 Other seizure disorders......Page 193 Summary......Page 194 References......Page 195 PET imaging in the assessment of normal and impaired cognitive function......Page 199 Cerebral metabolism......Page 200 Functional development and aging......Page 202 Alzheimer's disease and other dementing illnesses......Page 203 Prognosis......Page 205 Stroke......Page 206 References......Page 207 Alzheimer's disease......Page 210 Pick's disease......Page 212 Brain tumors......Page 213 Parkinson's disease......Page 214 Cerebrovascular disease......Page 216 Head trauma......Page 218 Epilepsy and other seizure disorders......Page 219 References......Page 221 PET imaging in the assessment of normal and impaired cognitive function......Page 227 Cerebral metabolism......Page 228 Functional development and aging......Page 230 Alzheimer's disease and other dementing illnesses......Page 231 Prognosis......Page 233 Stroke......Page 234 References......Page 235 Basis of MR imaging contrast......Page 238 Basis of MR imaging contrast agents......Page 239 Gadolinium chelates......Page 240 Methods of increasing gadolinium-induced contrast......Page 241 Iron oxide nanoparticles......Page 243 MR spectroscopy......Page 247 References......Page 249